Thousands of women sue Bayer over medical issues using Bayer's Essure
Skip to main content
MDHC_Logotype_white
Subscribe
  • My Account
  • Login
  • Subscribe
  • News
    • This Week's News
    • COVID-19
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • People
    • Regional News
    • Digital Edition
    • KPMG says deal activity will stay high in '21: 10 takeaways
      2 in 5 Americans live where COVID-19 strains hospital ICUs
      Biden's early approach to virus: Underpromise, overdeliver
      50% of Americans make resolutions. Fewer than 27% keep them over time.
      Data Points: Sticking with your resolutions
    • KPMG says deal activity will stay high in '21: 10 takeaways
      2 in 5 Americans live where COVID-19 strains hospital ICUs
      Biden's early approach to virus: Underpromise, overdeliver
      Two travel nurses wearing personal protective equipment.
      Healthcare providers face high costs, demand for agency staff as COVID-19 rages
    • Health suffers as rural hospitals close
      Medicare ACO participants fell in 2021
      Louisiana gets reports vaccine providers are discriminating
      'We know this is real': New clinics aid virus 'long-haulers'
    • Last-minute COVID costs cut into UnitedHealthcare's $396 million operating income
      CMS approves rule forcing insurers to ease prior authorization
      COVID-19 still a big uncertainty for insurers in 2021
      Health insurers' outlook boosted after Dems' Georgia win
    • It's a secret: California keeps key virus data from public
      lacewell_linda_supertinendent_dept_of_financial_services_8.47.jpg
      New York state investigates drug price spikes during pandemic
      Health experts blame rapid expansion for vaccine shortages
      HHS freezes rule targeting community health centers' drug discounts
    • KPMG says deal activity will stay high in '21: 10 takeaways
      By the Numbers: 20 largest healthcare investment banks in 2020
      Providers await new HHS coronavirus grant reporting deadline
      Operation Warp Speed Dr. Moncef Slaoui, Pfizer Group President Angela Hwang, Moderna CEO Stephane Bancel, CVS Health Executive Vice President Karen Lynch and McKesson CEO Brian Tyler participate in a panel discussion on the COVID-19 vaccine.
      Hospitals, drug companies strive to stand out virtually at JPM
    • Next Up Podcast: What to expect with telehealth and healthcare technology in the next 4 years - Transcript
      Dr. Karen DeSalvo
      Next Up Podcast: What to expect with telehealth and healthcare technology in the next 4 years
      A man in a room with servers.
      Momentum grows to outsource hospital tech functions in 2021
      5 things to know about Google's $2.1B Fitbit acquisition
    • 50% of Americans make resolutions. Fewer than 27% keep them over time.
      Data Points: Sticking with your resolutions
      An older man wearing a mask receiving a vaccine.
      Want more diversity in clinical trials? Start with the researchers
      Avocado
      Avocado a day keeps the doctor away
      U.K. chief scientist says new virus variant may be more deadly
    • Cerner names Erceg as new CFO
      Elizabeth Richter will serve as acting CMS administrator
      Providence names new chief financial officer
      Wisconsin's top health official departing for federal job
    • Midwest
    • Northeast
    • South
    • West
  • Insights
    • ACA 10 Years After
    • Best Practices
    • InDepth Special Reports
    • Innovations
    • The Affordable Care Act after 10 years
    • New care model helps primary-care practices treat obesity
      doctor with patient
      COVID-19 treatment protocol developed in the field helps patients recover
      Rachel Wyatt
      Project to curb pressure injuries in hospitals shows promise
      Yale New Haven's COVID-19 nurse-staffing model has long-term benefits
    • Dr. James Hildreth
      How medical education can help fight racism
      Modern Healthcare InDepth: Breaking the bias that impedes better healthcare
      Videos: Healthcare industry executives describe their encounters with racism
      Michellene Davis
      Healthcare leadership lacks the racial diversity needed to reduce health disparities
      Hospital divided into multiple pieces
      Health systems may be warming to offshoring, a mainstay practice for insurers
    • A phone screen showing the question, "Mary we hope this information was helpful and we'd like to keep guiding you. Are you interested in knowing when it's your turn to receive the vaccine?"
      Chatbots, texting campaigns help manage influx of COVID vax questions
      A woman with a wearable sensor talking to her provider.
      Wearable sensors help diagnose heart rhythm problems in West Virginia
      self service station
      COVID-19 pushes patient expectations toward self-service
      Targeting high-risk cancer patients with genetics
  • Transformation
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Highmark Health inks six-year cloud, tech deal with Google
      Study: 1 in 5 patients report discrimination when getting healthcare
      HHS proposes changing HIPAA privacy rules
      Android health records app launches at 230 health systems
    • California hospitals prepare ethical protocol to prioritize lifesaving care
      Amazon, JPMorgan Chase, Berkshire Hathaway disband Haven
      Digital pathways poised to reshape healthcare continuum in 2021
      Healthcare was the hardest hit by supply shortages across all U.S. industries
    • A phone screen showing the question, "Mary we hope this information was helpful and we'd like to keep guiding you. Are you interested in knowing when it's your turn to receive the vaccine?"
      Chatbots, texting campaigns help manage influx of COVID vax questions
      A woman with a wearable sensor talking to her provider.
      Wearable sensors help diagnose heart rhythm problems in West Virginia
      New care model helps primary-care practices treat obesity
      How hospitals are building on COVID-19 telehealth momentum
    • Regional insurers bet big on virtual-first plans
      MedPAC votes to boost hospital payments, freeze or cut other providers
      Most Next Gen ACOs achieved bonuses in 2019
      Congress recalibrates Medicare Physician Fee Schedule after lobbying
  • Data/Lists
    • Rankings/Lists
    • Interactive Databases
    • Data Points
    • Health Systems Financials
      Executive Compensation
      Physician Compensation
  • Op-Ed
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
    • Wellstar CEO calls adapting for the pandemic her bold move
      Howard P. Kern
      Recognizing the value of telehealth in its infancy
      Dr. Stephen Markovich
      A bold move helped take him from family doctor to OhioHealth CEO
      Dr. Bruce Siegel
      Why taking a hospital not-for-profit was Dr. Bruce Siegel’s boldest move
    • Barry Ostrowsky
      Ending racism is a journey taken together; the starting point must be now
      Laura Lee Hall and Gary Puckrein
      Increased flu vaccination has never been more important for communities of color
      John Daniels Jr.
      Health equity: Making the journey from buzzword to reality
      Mark C. Clement and David Cook
      We all need to 'do something' to fight inequities and get healthcare right, for every patient, every time
    •  Alan B. Miller
      Looking ahead with optimism as we continue to transform healthcare
      Dr. Bruce Siegel
      By protecting the healthcare safety net, Biden can put us on the path to a stronger country
      Healing healthcare: some ideas for triage by the new Congress, administration
      Dr. Sachin H. Jain
      Medicare for All? The better route to universal coverage would be Medicare Advantage for All
    • Letters: Eliminating bias in healthcare needs to be ‘deliberate and organic’
      Letters: Maybe dropping out of ACOs is a good thing for patients
      Letters: White House and Congress share blame for lack of national COVID strategy
      Letters: VA making strides to improve state veterans home inspections
    • Sponsored Content Provided By Optum
      How blockchain could ease frustration with the payment process
      Sponsored Content Provided By Optum
      Three steps to better data-sharing for payer and provider CIOs
      Sponsored Content Provided By Optum
      Reduce total cost of care: 6 reasons why providers and payers should tackle the challenge together
      Sponsored Content Provided By Optum
      Why CIOs went from back-office operators to mission-critical innovators
  • Awards
    • Award Programs
    • Nominate
    • Previous Award Programs
    • Other Award Programs
    • Best Places to Work in Healthcare Logo for Navigation
      Nominations Open - Best Places to Work in Healthcare
      Nominations Open - Health Care Hall of Fame
      Nominations Open - 50 Most Influential Clinical Executives
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top 25 Innovators
    • Top 25 Minority Leaders
    • Top 25 Women Leaders
    • Excellence in Nursing Awards
    • Design Awards
    • Top 25 COOs in Healthcare
    • 100 Top Hospitals
    • ACHE Awards
  • Events
    • Conferences
    • Galas
    • Webinars
    • COVID-19 Event Tracker
    • Leadership Symposium
    • Healthcare Transformation Summit
    • Women Leaders in Healthcare Conference
    • Workplace of the Future Conference
    • Strategic Marketing Conference
    • Social Determinants of Health Symposium
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Minority Leaders Gala (2022)
    • Top 25 Women Leaders Gala
  • Listen
    • Podcast - Next Up
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
    • Dr. Karen DeSalvo
      Next Up Podcast: What to expect with telehealth and healthcare technology in the next 4 years
      Carter Dredge
      Next Up Podcast: Ready, set, innovate! Innovation and disruption in healthcare
      Next Up Podcast: COVID-19, social determinants highlight health inequities — what next?
      Ceci Connolly
      Next Up Podcast: How to navigate the murky post-election waters
    • Beyond the Byline: Regulators aim to boost value push with fraud and abuse law updates
      An older man wearing a mask receiving a vaccine.
      Beyond the Byline: Verifying information on the chaotic COVID-19 vaccine rollout
      doctor burnout
      Beyond the Byline: How healthcare supply chain struggles contribute to employee burnout
      Beyond the Byline: Covering race and diversity in the healthcare industry
    • Leading intention promote diversity and inclusion
      Introducing Healthcare Insider Podcast
    • The Check Up: Chip Kahn
      The Check Up: Chip Kahn of the Federation of American Hospitals
      The Check Up: Trenda Ray
      The Check Up: Trenda Ray of the University of Arkansas for Medical Sciences
      The Check Up: Dr. Kenneth Davis
      The Check Up: Dr. Kenneth Davis of Mount Sinai Health System
      The Check Up: Dr. Thomas McGinn
      The Check Up: Dr. Thomas McGinn of CommonSpirit Health
    • Video: Ivana Naeymi Rad of Intelligent Medical Objects
  • MORE +
    • Advertise
    • Media Kit
    • Newsletters
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Technology
April 29, 2017 01:00 AM

Thousands of women sue Bayer over medical issues using Bayer's Essure

Drug and devicemakers must weigh the impact of litigation and public relations battle when allegations of patient harm arise

Elizabeth Whitman
  • Tweet
  • Share
  • Share
  • Email
  • More
    Print
    Getty Images
    Ellen Hanrahan is one of thousands of women alleging harm from Essure. Hanrahan gave birth to her daughter Leena in 2012, despite having the permanent sterilization device implanted two years earlier.

    After giving birth to her third daughter in 2013, Rina Kellogg was done having children. She wanted to have her tubes tied, but her OB-GYN suggested she get a sterilization implant called Essure.

    "She said it was the latest and greatest technology, and that it was like putting a stent in your heart," said Kellogg, a 36-year-old living in Spring, Texas. "I trusted her and I went ahead and did the procedure."

    Essure consists of two sets of tiny coils-one of stainless steel, wound with polyethylene terephthalate polyester fibers, nestled in a larger nickel-titanium coil-that are implanted in a woman's fallopian tubes. Scar tissue is supposed to form around them, securing the coils and blocking the tubes so that eggs cannot be fertilized.

    After the implantation in August 2014, Kellogg was in pain. But she assumed her body needed time to adjust. By Christmas, however, she was in agony with cramping and profuse bleeding. During a follow-up visit, Kellogg's doctor dismissed her symptoms as results of stopping hormonal birth control. She also told Kellogg, 33 at the time, that she was "getting older."

    The bleeding lasted for more than a year. At 34, Kellogg had a hysterectomy to remove the device. Still, her medical problems persisted. Since 2013, she has been diagnosed with chronic fatigue, irritable bowel syndrome, fibromyalgia, insomnia and other medical issues-a far cry from when she worked 50-hour weeks as a special-education teacher, all while pregnant with her second child.

    THE TAKEAWAY

    Companies face significant legal, financial and PR pitfalls when patient-safety issues arise.

    "I literally went from having no medical problems before this, to bleeding for about 424 days, to having a hysterectomy as a young mother with three kids," Kellogg said. "I'm still having issues, even though I got it out."

    Kellogg is among a legion of women who are speaking up about severe medical problems they say were triggered by Essure. In recent years, thousands of women alleging harm from Essure have filed lawsuits against Bayer, the device's manufacturer.

    Some experts and physicians predict that these efforts will drive Essure off the market, not necessarily because it's deemed unsafe, but because it will no longer be marketable. In the past, other device and drugmakers have done just that after lawsuits, settlements and Food and Drug Administration safety warnings—not formal recalls—made the products a bigger liability than they were worth. Until companies draw that line, patients still face risks.

    "I'll be surprised if Essure is being sold 15 months from now," said Erik Gordon, a professor at the Ross School of Business at the University of Michigan. "If Bayer doesn't pull it, I think the FDA will."

    Essure was developed in the 1990s by California-based company Conceptus, which Germany-based Bayer acquired in 2013. Between Nov. 4, 2002, when the FDA approved Essure, and Dec. 31, 2016, the FDA received 14,919 reports documenting device migration, organ perforation, severe pain and a slew of other adverse reactions.

    In 2016, the FDA mandated a black box warning, the highest-level alert, for Essure. Patients and their advocates continue to call for it to be taken off the U.S. market, as Brazil did in February, when it suspended the importation, distribution and marketing of Essure.

    Last year, impairment losses connected to Essure cost Bayer $413 million, according to the company's 2016 annual report. The company expects it will face even more lawsuits.

    When asked whether it was considering pulling the device from the market, Bayer said it "stands behind Essure and its positive benefit-risk profile."

    "The safety and efficacy of Essure, the only FDA-approved method of permanent birth control with a non-incisional procedure, are supported by more than a decade of science as well as real-world clinical experience," according to Bayer.

    But if Bayer does stop marketing the device, it would not be unprecedented. Other companies have withdrawn medical devices from the market voluntarily in the past without the FDA issuing a recall.

    In 2014, Johnson & Johnson pulled three types of power morcellators, which are used to extract fibroid tumors, after they were found to have a high risk of spreading cancer. Those devices constituted a small portion of its revenue.

    The FDA did not ban or recall the morcellators, but it sent a safety advisory to doctors warning them not to use the devices for uterine fibroids. After that notice went out, J&J pulled them off the market.

    "J&J could've kept selling it," Gordon said, referring to the morcellators.

    In other cases, J&J stopped selling Pinnacle hip devices in 2013, the same year it paid $2.5 billion to compensate patients over a different product, ASR hip devices. In 2012, its Ethicon division stopped selling mesh urinary implants, over which women had filed thousands of lawsuits against the company alleging harm. The following year, a jury ordered J&J to pay $3.35 million to a woman because the company did not adequately warn her doctor about the implant's potential risks.

    Last October, St. Jude Medical recalled nearly 400,000 defibrillators, whose batteries could fail unexpectedly. The FDA recently warned that the company had nevertheless somehow allowed seven patients to be implanted with them, even after the recall. One stock analyst said that could serve as a PR "black eye" for Abbott, which acquired St. Jude in January, the Minneapolis Star Tribune reported.

    Costly litigation, settlements and negative publicity are a few precipitating factors that can push a company over the tipping point to pull a device.

    "For the company, it's more of a business decision," Gordon said. "At some point, your risk management people look at it and say it's just too financially risky to keep selling these things."

    Bayer said it has sold 750,000 Essure devices since 2002, the majority of them in the U.S. It does not release annual sales figures, but the 750,000 figure hasn't changed for at least four years. In a 2013 filing to the Securities and Exchange Commission, Conceptus said it had distributed that same number of Essure devices.

    Data from the ECRI Institute, a Philadelphia-based not-for-profit that researches patient safety issues, suggest that some providers are abandoning Essure. In 2014, 365 members of ECRI's PriceGuide service spent $8.34 million to purchase 4,836 Essure devices. In 2015, 299 members spent $5.79 million on 3,244 devices. The following year, the numbers fell further, with 180 members spending $1.98 million on 1,122 devices.

    The data have a few important limitations. The majority of PriceGuide members are hospitals and surgical centers. The numbers do not necessarily include purchases by physicians. They also cover only a span of three years, and so it's not clear whether the decline is the continuation of sales trends prior to 2014 or whether it represents a change.

    Still, physician feedback corroborates the diminished interest in Essure indicated by those declining sales, regardless of prior trends.

    In February, Modern Healthcare polled OB-GYNs about Essure through Sermo, an online social network for doctors. Of the 387 OB-GYNs surveyed, 272 said they had implanted Essure devices in patients. Of those doctors, 175, or 64%, said that their Essure implants per year in the past five years had declined significantly; 42 doctors, or 15%, said the implants had declined a little.

    "In the end, the doctors are the biggest gatekeepers," Gordon said. If patients tell physicians that they don't want a device or drug, then physicians, fearing malpractice suits, begin to abandon it, he explained. If sales fall, then the company loses its incentive to keep selling the device, especially if it's increasingly connected with lawsuits and negative attention.

    In anonymous comments submitted with the Sermo poll, OB-GYNs in the U.S. offered a mix of opinions. "Essure provides a form of permanent sterilization that is particularly helpful for patients who are not good candidates for abdominal surgery," one said. "However, since reversible options . . . are equally effective, I will be monitoring the risk-benefit profile of Essure closely."

    Another said that when the procedure goes well, Essure was "a great method of sterilization," but "when things don't go well (there) can be significant issues trying to remove the implants."

    Several said they had stopped offering Essure or significantly scaled back due to side effects.

    One OB-GYN weighed in​ on the "paranoia" around Essure, calling it "one of the worst issues I deal with" and saying it had caused the doctor to perform many more unnecessary laparoscopies.

    Amanda Yunker, an assistant professor of obstetrics and gynecology at Vanderbilt University School of Medicine in Nashville, said she has seen "a steady increase" in the number of patients seeking removal in the past few years. She estimated she has removed 80 to 100 Essure devices, none of which she implanted.

    Yunker's practice is centered around pelvic pain, and she has noticed that such pain is a common symptom after patients had Essure implanted. "You're never 100% sure, because pain is very subjective and it's multifactorial. There could be a lot of things that contribute to pelvic pain," Yunker said. Nevertheless, "the majority of them definitely had improvement in their pain when it (Essure) was removed," she said.

    No medical device or drug is perfectly safe. The fundamental challenge with Essure is knowing which patients are apt to do well with it and which are prone to severe, even debilitating complications. The FDA's position is that those in the former category should have access to the device, even while those who fall in the latter are protected.

    "The unfortunate thing is, we don't know where people fall prior to implanting the device," Yunker said.

    Many studies focusing on Essure have compared aspects of the procedure, such as methods of pain management or follow-up testing. They have not sought to find relationships between a patient's medical profile prior to the procedure and her outcomes afterward.

    According to a systematic review of Essure by researchers in Finland and published in the journal Fertility and Sterility in 2010, long-term data on Essure's safety and efficacy were still unavailable, and there were no randomized controlled studies of the device. The researchers also noted that most studies on Essure have been funded by Bayer.

    The FDA has required Bayer to conduct a new study of Essure's benefits and risks that it hopes will shed light on the complications that afflict women who have Essure, compared to those who have tubal ligation.

    Essure patients, especially women who are part of the Facebook group Essure Problems, and their advocates argue that the only way to prevent further harm is to remove the device from the market entirely.

    But the FDA maintains that the device is safe for a majority of women and that pulling the device would deprive them of an important birth-control option. It also says that the required black box warning does enough to protect patients.

    "After significant review and analysis of available information, we believe Essure is safe and effective for many women-but also that some women experience very serious and sometimes debilitating problems," said Deborah Kotz, an FDA spokeswoman.

    Meanwhile, the more than 14,000 reports to the agency have "not changed the FDA's determination regarding the benefits and risks of Essure," Kotz said. Essure offers benefits despite these side effects, she added, noting that it is currently the only non-incisional form of permanent birth control.

    Kotz said that the updated labeling "helps to ensure that patients are appropriately informed of the risks" from Essure. "Banning Essure would remove the device from the market for all patients-and would limit the options available to physicians and patients." Natalie Hansen, a 47-year-old living in Mooresville, N.C., and a former Essure patient, is skeptical of that approach.

    Before she was implanted with Essure in 2011, Hansen recalled, her doctor dismissed her queries about the risk of an allergic reaction to nickel, which Hansen knew even then that she was sensitive to. And since then, she has made more than 70 doctor's visits and endured searing pain, depression, cysts, severe bloating, autoimmune symptoms and a host of other medical problems. Yet she considers herself lucky.

    In early April, she had a hysterectomy, and with it, her pain and complications have disappeared-almost miraculously. Her sense of humor, dampened for years by the constant pain, has resurfaced. "Despite having organs taken out, I haven't felt this good in years," she said.

    Hansen said that doctors today are fully aware of the risks of Essure, even after the black box warning the FDA issued in 2016. "Who's holding them accountable to make sure they're actually giving this information to patients?" she asked.​

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    Next Up Podcast: What to expect with telehealth and healthcare technology in the next 4 years
    Next Up Podcast: What to expect with telehealth and healthcare technology in the next 4 years
    Next Up Podcast: What to expect with telehealth and healthcare technology in the next 4 years - Transcript
    Sponsored Content
    Get Free Newsletters

    Sign up for free enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today

    The weekly magazine, websites, research and databases provide a powerful and all-encompassing industry presence. We help you make informed business decisions and lead your organizations to success.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS
    • Instagram

    Stay Connected

    Join the conversation with Modern Healthcare through our social media pages

    MDHC_Logotype_white
    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2021. Crain Communications, Inc. All Rights Reserved.
    • News
      • This Week's News
      • COVID-19
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition
    • Insights
      • ACA 10 Years After
      • Best Practices
      • InDepth Special Reports
      • Innovations
    • Transformation
      • Patients
      • Operations
      • Care Delivery
      • Payment
    • Data/Lists
      • Rankings/Lists
      • Interactive Databases
      • Data Points
    • Op-Ed
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Awards
      • Award Programs
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top 25 Innovators
        • Top 25 Minority Leaders
        • Top 25 Women Leaders
      • Nominate
      • Previous Award Programs
        • Excellence in Nursing Awards
        • Design Awards
        • Top 25 COOs in Healthcare
      • Other Award Programs
        • 100 Top Hospitals
        • ACHE Awards
    • Events
      • Conferences
        • Leadership Symposium
        • Healthcare Transformation Summit
        • Women Leaders in Healthcare Conference
        • Workplace of the Future Conference
        • Strategic Marketing Conference
        • Social Determinants of Health Symposium
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Minority Leaders Gala (2022)
        • Top 25 Women Leaders Gala
      • Webinars
      • COVID-19 Event Tracker
    • Listen
      • Podcast - Next Up
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • MORE +
      • Advertise
      • Media Kit
      • Newsletters
      • Jobs
      • People on the Move
      • Reprints & Licensing